Advanced NETs of Lung or GI Origin: Update of RADIANT-4 Study

Speaker: Ian Chau

Effective therapeutic options for advanced, nonfunctional NETs of lung or GI origin are limited, but everolimus is a promising effective treatment as RADIANT-4 study shows. Updated results from this phase III trial were presented at the ESMO Asia 2015 Congress in Singapore. Everolimus showed 7.1 month prolongation of PFS compared to placebo. According to I. Chau these results will be practice-changing; the data are exciting especially for lung NETs that are poor prognostic tumours with a lack of quality data from previous studies.

Discussion Points

  • What are current limitations for effectively treating advances, non-functional NETs of lung or GI origin?
  • What is the rationale of RADIANT-4 study?
  • What are the main results from the study?
  • What would be the impact of these results on clinical practice?